immuno-oncology

Communiqué de presse

iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

12 mai 2022 adenosine pathway, anti-TIGIT antibody, EOS-448, Fc gamma receptor (Fc?R), ...

Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with […]

Communiqué de presse

U.S. Food and Drug Administration Approves Nivolumab + Ipilimumab Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

27 mai 2020 Adam Lenkowsky, Bristol Myers Squibb, CART Cells, CheckMate -9LA, ...

In CheckMate -9LA, nivolumab + ipilimumab combined with two cycles of chemotherapy demonstrated superior overall survival versus chemotherapy, regardless […]

immuno-oncology

Communiqué de presse

iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

Communiqué de presse

U.S. Food and Drug Administration Approves Nivolumab + Ipilimumab Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Kiosque

Autres numéros

Brèves

Réseaux sociaux